A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer
Completed
Cascadian Therapeutics Inc.
Phase 1
2014-02-28
The purpose of this study is to determine the maximal tolerated dose (MTD) or recommended
dose (RD) and to assess the safety and tolerability of tucatinib (ONT-380) combined with
ado-trastuzumab emtansine (T-DM1) in patients with HER2+ breast cancer.
A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer
Completed
Seagen Inc.
Phase 1
2014-02-28
The purpose of this study is to determine the maximal tolerated dose (MTD) or recommended
dose (RD) and to assess the safety and tolerability of tucatinib (ONT-380) combined with
ado-trastuzumab emtansine (T-DM1) in patients with HER2+ breast cancer.
A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer
Completed
Cascadian Therapeutics Inc.
Phase 1
2013-12-31
The purpose of this study is to determine the maximal tolerated dose (MTD) or recommended
phase 2 dose (RP2D) of tucatinib (ONT-380) and to assess the safety and tolerability of
tucatinib (ONT-380) combined with capecitabine alone, trastuzumab alone and with both
capecitabine and trastuzumab in patients with HER2+ metastatic breast cancer.
A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer
Completed
Seagen Inc.
Phase 1
2013-12-31
The purpose of this study is to determine the maximal tolerated dose (MTD) or recommended
phase 2 dose (RP2D) of tucatinib (ONT-380) and to assess the safety and tolerability of
tucatinib (ONT-380) combined with capecitabine alone, trastuzumab alone and with both
capecitabine and trastuzumab in patients with HER2+ metastatic breast cancer.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.